お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:世界の慢性閉塞性肺疾患治療市場:産業分析、規模、シェア、成長、動向、および予測(2019年~2027年)
市場調査レポート
商品コード
799186

世界の慢性閉塞性肺疾患治療市場:産業分析、規模、シェア、成長、動向、および予測(2019年~2027年)

Chronic Obstructive Pulmonary Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版日: | 発行: Transparency Market Research | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.72円
世界の慢性閉塞性肺疾患治療市場:産業分析、規模、シェア、成長、動向、および予測(2019年~2027年)
出版日: 2019年10月16日
発行: Transparency Market Research
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは世界の慢性閉塞性肺疾患(COPD)治療市場について調査しており、市場機会、成長および阻害要因、薬剤クラス・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 序文

  • 市場の定義・範囲
  • 市場セグメンテーション
  • 主な調査目的
  • 調査ハイライト

第2章 前提条件および調査方法

第3章 エグゼクティブサマリー

第4章 市場の概要

  • イントロダクション
    • 薬剤クラスの定義
    • 産業の進展/開発
  • 概要
  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 市場収益予測
    • 市場収益予測

第5章 市場の展望

  • COPD治療のための革新的なソリューション
  • パイプライン分析

第6章 市場分析:薬剤クラス別

  • 概要・定義
  • 主な調査結果/開発
  • 市場収益予測
    • 併用療法
    • コルチコステロイド
    • 気管支拡張剤
    • ホスホジエステラーゼ4阻害剤
    • ムコキネティクス
    • その他
  • 市場の魅力分析

第7章 市場分析:流通チャネル別

  • 導入と定義
  • 主な調査結果/開発
  • 市場収益予測
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力分析

第8章 市場分析:地域別

  • 主な調査結果
  • 市場収益予測
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析

第9章 北米

第10章 欧州

第11章 アジア太平洋地域

第12章 ラテンアメリカ

第13章 中東・アフリカ

第14章 競合情勢

  • 市場参入企業:競合マトリックス(企業の階層・規模別)
  • 市場シェア/ランキング分析(2018年)
  • 企業プロファイル
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • GlaxoSmithKline plc
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Sunovion Pharmaceuticals Inc. (大日本住友製薬株式会社)
    • CHIESI Farmaceutici SpA
    • Orion Corporation
    • Mylan NV
図表

List of Tables

  • Table 01: Pipeline Analysis
  • Table 02: Pipeline Analysis
  • Table 03: Pipeline Analysis
  • Table 04: Pipeline Analysis
  • Table 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 07: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 08: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 09: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region, 2017-2027
  • Table 10: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 11: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 12: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 13: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 14: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country, 2017-2027
  • Table 15: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 16: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 17: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 18: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 19: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 20: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 21: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 22: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 23: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 24: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 25: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 26: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 27: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 28: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 29: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 30: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 31: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 32: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 33: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 34: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

List of Figures

  • Figure 01: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) and Distribution, by Region, 2018 and 2027
  • Figure 02: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Drug Class, 2018
  • Figure 03: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 04: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Combination Therapy, 2017-2027
  • Figure 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bronchodilators, 2017-2027
  • Figure 07: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2017-2027
  • Figure 08: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Phosphodiesterase Type 4 Inhibitor, 2017-2027
  • Figure 09: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Mucokinetics, 2017-2027
  • Figure 10: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2017-2027
  • Figure 11: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 12: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2027
  • Figure 13: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2017-2027
  • Figure 14: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2017-2027
  • Figure 15: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2017-2027
  • Figure 16: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 17: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Region, 2018 and 2027
  • Figure 18: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Region, 2019-2027
  • Figure 19: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 20: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 21: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 23: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 24: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 25: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country, 2019-2027
  • Figure 26: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 27: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 28: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027

"Figure 29: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

  • Figure 30: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 31: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 32: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 33: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 34: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 35: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027

"Figure 36: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

  • Figure 37: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 - 2027
  • Figure 38: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 39: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 40: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 41: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 42: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027

"Figure 43: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

  • Figure 44: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 - 2027
  • Figure 45: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 46: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 47: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 48: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 49: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027

"Figure 50: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

  • Figure 51: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019?2027
  • Figure 52: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 53: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 54: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share, by Company, 2018
  • Figure 55: AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 56: AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 57: AstraZeneca Breakdown of Net Sales (%), by Region, 2018
  • Figure 58: AstraZeneca Breakdown of Net Sales (%), by Product Segment, 2018
  • Figure 59: Boehringer Ingelheim International GmbH, Human Pharmaceuticals Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 60: Boehringer Ingelheim International GmbH R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 61: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Region, 2018
  • Figure 62: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 63: GlaxoSmithKline plc Respiratory (Pharmaceuticals) Business Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 64: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 65: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region, 2018
  • Figure 66: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 67: Novartis AG COPD Portfolio Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 68: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 69: Novartis AG Breakdown of Net Sales (%), by Country, 2018
  • Figure 70: Novartis AG Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 71: Teva Pharmaceutical Industries Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 72: Teva Pharmaceutical Industries Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 73: Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Geography, 2018
  • Figure 74: Sumitomo Dainippon Pharma Co., Ltd Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 75: Sumitomo Dainippon Pharma Co., Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 76: Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Geography, 2018
  • Figure 77: Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Product Segment, 2018
  • Figure 78: CHIESI Farmaceutici S.p.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 79: CHIESI Farmaceutici S.p.A. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 80: CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Geography, 2018
  • Figure 81: CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Therapeutic Area(Business Segment), 2018
  • Figure 82: Orion Corporation Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 83: Orion Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 84: Orion Corporation Breakdown of Net Sales (%), by Geography, 2018
  • Figure 85: Orion Corporation Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 86: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 87: Mylan N.V. Breakdown of Net Sales, by Geography, 2018
  • Figure 88: Mylan N.V. R&D Expenses (US$ Mn), 2017 and 2018
目次

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Scope of the Report

TMR's report on the global chronic obstructive pulmonary disease (COPD) treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period of 2019 to 2027. The report provides the overall market revenue of the global chronic obstructive pulmonary disease treatment market for the period of 2017-2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global chronic obstructive pulmonary disease treatment market during the forecast period.

The report is prepared after extensive research. Primary research involves bulk of the research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global COPD treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of the top-down and bottom-up approaches to study various phenomena in the global chronic obstructive pulmonary disease treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global chronic obstructive pulmonary disease treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global chronic obstructive pulmonary disease treatment market.

The report delves into the competition landscape of the global COPD treatment market. Key players operating in the global chronic obstructive pulmonary disease treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of the players in the global COPD treatment market that have been profiled in this report.

Key Questions Answered in the COPD Treatment Market Report

What is the scope of growth for companies in the global chronic obstructive pulmonary disease treatment market?

What will be the Y-o-Y growth of the global chronic obstructive pulmonary disease treatment market between 2019 and 2027?

Will North America continue to remain the most profitable regional market for COPD treatment providers?

Which factors will impede the growth of the global chronic obstructive pulmonary disease treatment market during the forecast period?

Which are the leading companies in the global COPD treatment market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct a comprehensive research on the growth of the global chronic obstructive pulmonary disease treatment market, and arrive at conclusions on the future growth prospects of the COPD treatment market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary sources referred to by analysts during the production of the global chronic obstructive pulmonary disease treatment market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR's study on the COPD treatment market as primary sources.

These primary and secondary sources have provided exclusive information during interviews, which serves as a validation from chronic obstructive pulmonary disease treatment market leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global chronic obstructive pulmonary disease treatment market with accuracy. The study also uses the top-down approach to assess the numbers for each segment, and the bottom-up approach to counter-validate them. This has helped in reaching TMR's estimates on the future prospects of the global chronic obstructive pulmonary disease treatment market more reliably and accurately.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Class Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, 2017-2027
    • 4.4.1. Market Revenue (US$ Mn) Projection

5. Market Outlook

  • 5.1. Innovative Solutions for COPD Treatment
  • 5.2. Pipeline Analysis

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 6.3.1. Combination Therapy
      • 6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 6.3.1.3. Triple Therapy
      • 6.3.1.4. Others
    • 6.3.2. Corticosteroids
    • 6.3.3. Bronchodilators
      • 6.3.3.1. Long Acting Beta Agonist (LABA)
      • 6.3.3.2. Short Acting Beta Agonist (SABA)
      • 6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 6.3.4. Phosphodiesterase Type 4 Inhibitors
    • 6.3.5. Mucokinetics
    • 6.3.6. Others
  • 6.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Drug Class

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Distribution Channel

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by region

9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 9.2.1. Combination Therapy
      • 9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 9.2.1.3. Triple Therapy
      • 9.2.1.4. Others
    • 9.2.2. Corticosteroids
    • 9.2.3. Bronchodilators
      • 9.2.3.1. Long Acting Beta Agonist (LABA)
      • 9.2.3.2. Short Acting Beta Agonist (SABA)
      • 9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 9.2.4. Phosphodiesterase Type 4 Inhibitors
    • 9.2.5. Mucokinetics
    • 9.2.6. Others
  • 9.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
    • 9.5.1. By Drug Class
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country/Sub-region

10. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 10.2.1. Combination Therapy
      • 10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 10.2.1.3. Triple Therapy
      • 10.2.1.4. Others
    • 10.2.2. Corticosteroids
    • 10.2.3. Bronchodilators
      • 10.2.3.1. Long Acting Beta Agonist (LABA)
      • 10.2.3.2. Short Acting Beta Agonist (SABA)
      • 10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 10.2.4. Phosphodiesterase Type 4 Inhibitors
    • 10.2.5. Mucokinetics
    • 10.2.6. Others
  • 10.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Russia
    • 10.4.7. Rest of Europe
  • 10.5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
    • 10.5.1. By Drug Class
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 11.2.1. Combination Therapy
      • 11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 11.2.1.3. Triple Therapy
      • 11.2.1.4. Others
    • 11.2.2. Corticosteroids
    • 11.2.3. Bronchodilators
      • 11.2.3.1. Long Acting Beta Agonist (LABA)
      • 11.2.3.2. Short Acting Beta Agonist (SABA)
      • 11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 11.2.4. Phosphodiesterase Type 4 Inhibitors
    • 11.2.5. Mucokinetics
    • 11.2.6. Others
  • 11.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
  • 11.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
    • 11.5.1. By Drug Class
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 12.2.1. Combination Therapy
      • 12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 12.2.1.3. Triple Therapy
      • 12.2.1.4. Others
    • 12.2.2. Corticosteroids
    • 12.2.3. Bronchodilators
      • 12.2.3.1. Long Acting Beta Agonist (LABA)
      • 12.2.3.2. Short Acting Beta Agonist (SABA)
      • 12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 12.2.4. Phosphodiesterase Type 4 Inhibitors
    • 12.2.5. Mucokinetics
    • 12.2.6. Others
  • 12.3. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Retail Pharmacies
    • 12.3.3. Online Pharmacies
  • 12.4. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
    • 12.5.1. By Drug Class
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 13.2.1. Combination Therapy
      • 13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 13.2.1.3. Triple Therapy
      • 13.2.1.4. Others
    • 13.2.2. Corticosteroids
    • 13.2.3. Bronchodilators
      • 13.2.3.1. Long Acting Beta Agonist (LABA)
      • 13.2.3.2. Short Acting Beta Agonist (SABA)
      • 13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 13.2.4. Phosphodiesterase Type 4 Inhibitors
    • 13.2.5. Mucokinetics
    • 13.2.6. Others
  • 13.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 13.3.1. Hospital Pharmacies
    • 13.3.2. Retail Pharmacies
    • 13.3.3. Online Pharmacies
  • 13.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 13.4.1. GCC
    • 13.4.2. South Africa
    • 13.4.3. Israel
    • 13.4.4. Rest of Middle East & Africa
  • 13.5. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
    • 13.5.1. By Drug Class
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share/ranking Analysis By Company (2018)
  • 14.3. Company Profiles
    • 14.3.1. AstraZeneca
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Company Financials
      • 14.3.1.3. Growth Strategies
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. Boehringer Ingelheim International GmbH
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Company Financials
      • 14.3.2.3. Growth Strategies
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. GlaxoSmithKline plc
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Company Financials
      • 14.3.3.3. Growth Strategies
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Novartis AG
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Company Financials
      • 14.3.4.3. Growth Strategies
      • 14.3.4.4. SWOT Analysis
    • 14.3.5. Teva Pharmaceutical Industries Ltd.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Company Financials
      • 14.3.5.3. Growth Strategies
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Company Financials
      • 14.3.6.3. Growth Strategies
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. CHIESI Farmaceutici S.p.A.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Company Financials
      • 14.3.7.3. Growth Strategies
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Orion Corporation
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Company Financials
      • 14.3.8.3. Growth Strategies
      • 14.3.8.4. SWOT Analysis
    • 14.3.9. Mylan N.V.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Company Financials
      • 14.3.9.3. Growth Strategies
      • 14.3.9.4. SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.